p.88 抽出テキスト

pressures for the diagnosis of constrictive pericarditis. Circulation 1996;93: 2007–13. https://doi.org/10.1161/01.cir.93.11.2007 230. Dorfs S, Zeh W, Hochholzer W, Jander N, Kienzle RP, Pieske B, et al. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J 2014;35:3103–12. https://doi.org/10.1093/eurheartj/ehu315 231. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010;3:588–95. https://doi.org/10.1161/ CIRCHEARTFAILURE.109.930701 232. van den Boogert TPW, Claessen B, van Randen A, van Schuppen J, Boekholdt SM, Beijk MAM, et al. Implementation of CT coronary angiography as an alternative to invasive coronary angiography in the diagnostic work-up of noncoronary cardiac surgery, cardiomyopathy, heart failure and ventricular arrhythmias. J Clin Med 2021;10:2374. https://doi.org/10.3390/jcm10112374 233. Chow BJW, Coyle D, Hossain A, Laine M, Hanninen H, Ukkonen H, et al. Computed tomography coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE-HF 1C). Eur Heart J Cardiovasc Imaging 2021;22:1083–90. https://doi.org/10.1093/ehjci/ jeaa109 234. Andreini D, Pontone G, Bartorelli AL, Agostoni P, Mushtaq S, Bertella E, et al. Sixty-four-slice multidetector computed tomography: an accurate imaging modality for the evaluation of coronary arteries in dilated cardiomyopathy of unknown etiology. Circ Cardiovasc Imaging 2009;2:199–205. https://doi. org/10.1161/CIRCIMAGING.108.822809 235. Merkely B, Hatala R, Merkel E, Szigeti M, Veres B, Fabian A, et al. Benefits of upgrading right ventricular to biventricular pacing in heart failure patients with atrial fibrillation. Europace 2024;26:euae179. https://doi.org/10. 1093/europace/euae179 236. Kaye G, Ng JY, Ahmed S, Valencia D, Harrop D, Ng ACT. The prevalence of pacing-induced cardiomyopathy (PICM) in patients with long term right ventricular pacing—is it a matter of definition? Heart Lung Circ 2019;28:1027–33. https://doi.org/10.1016/j.hlc.2018.05.196 237. Khurshid S, Epstein AE, Verdino RJ, Lin D, Goldberg LR, Marchlinski FE, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. Heart Rhythm 2014;11:1619–25. https://doi.org/10.1016/j.hrthm. 2014.05.040 238. Kiehl EL, Makki T, Kumar R, Gumber D, Kwon DH, Rickard JW, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm 2016;13:2272–8. https://doi.org/10. 1016/j.hrthm.2016.09.027 239. Somma V, Ha FJ, Palmer S, Mohamed U, Agarwal S. Pacing-induced cardiomyopathy: a systematic review and meta-analysis of definition, prevalence, risk factors, and management. Heart Rhythm 2023;20:282–90. https://doi. org/10.1016/j.hrthm.2022.09.019 240. Ganapathy AV, Monjazeb S, Ganapathy KS, Shanoon F, Razavi M. ‘Asymptomatic’ persistent or permanent atrial fibrillation: a misnomer in selected patients. Int J Cardiol 2015;185:112–3. https://doi.org/10.1016/j. ijcard.2015.03.122 241. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022; 400:757–67. https://doi.org/10.1016/S0140-6736(22)01429-5 242. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008. https://doi.org/10.1056/ NEJMoa1911303 243. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413–24. https://doi.org/10.1056/NEJMoa2022190 244. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–61. https://doi.org/10.1056/NEJMoa2107038 245. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089–98. https://doi.org/10.1056/ NEJMoa2206286 246. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020;396:819–29. https://doi.org/10.1016/S0140-6736(20)31824-9 247. Gao M, Bhatia K, Kapoor A, Badimon J, Pinney SP, Mancini DM, et al. SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: a systematic review and meta-analysis. JAMA Netw Open 2024;7:e245135. https://doi.org/10.1001/jamanetworkopen.2024.5135 248. Oriecuia C, Tomasoni D, Sala I, Bonfioli GB, Adamo M, Gussago C, et al. Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2024;10: 147–57. https://doi.org/10.1093/ehjcvp/pvad088 249. Kondo T, Jhund PS, Gasparyan SB, Yang M, Claggett BL, McCausland FR, et al. A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials. Nat Med 2024;30:1432–9. https://doi.org/10.1038/s41591-024-02941-8 250. Sharma A, Ferreira JP, Zannad F, Pocock SJ, Filippatos G, Pfarr E, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-preserved trial. Eur J Heart Fail 2023;25:1337–48. https://doi.org/10.1002/ejhf.2857 251. Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Bohm M, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation 2021; 143:298–309. https://doi.org/10.1161/CIRCULATIONAHA.120.050391 252. Mc Causland FR, Claggett BL, Vaduganathan M, Desai AS, Jhund P, de Boer RA, et al. Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial. JAMA Cardiol 2023;8:56–65. https://doi.org/10.1001/jamacardio.2022.4210 253. Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation 2021;143: 310–21. https://doi.org/10.1161/CIRCULATIONAHA.120.051685 254. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–17. https://doi.org/10.1056/NEJM199909023411001 255. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–92. https://doi.org/10.1056/NEJMoa1313731 256. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21. https://doi.org/10.1056/NEJMoa1009492 257. Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2024;391:1475–85. https://doi.org/10.1056/ NEJMoa2407107 258. Harrington JL, Canonico ME, El Rafei A, Solomon SD, Teerlink JR, Vaduganathan M, et al. Nonsteroidal and steroidal mineralocorticoid antagonists: rationale, evidence, and unanswered questions. JACC Heart Fail 2025; 13:102637. https://doi.org/10.1016/j.jchf.2025.102637 259. Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2022;24:603–19. https://doi.org/10. 1002/ejhf.2471 260. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149–58. https://doi.org/10. 1016/s0167-5273(01)00600-3 261. Damman K, Kjekshus J, Wikstrand J, Cleland JG, Komajda M, Wedel H, et al. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. Eur J Heart Fail 2016;18:328–36. https:// doi.org/10.1002/ejhf.462 262. Costanzo MR, Stevenson LW, Adamson PB, Desai AS, Heywood JT, Bourge RC, et al. Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. JACC Heart Fail 2016; 4:333–44. https://doi.org/10.1016/j.jchf.2015.11.011 263. Galve E, Mallol A, Catalan R, Palet J, Mendez S, Nieto E, et al. Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction. Eur J Heart Fail 2005;7:892–8. https://doi.org/10.1016/j.ejheart.2004.09.006 264. Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol 1994;73:881–6. https://doi.org/10.1016/0002- 9149(94)90815-x 265. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:137–55. https://doi.org/10.1002/ ejhf.1369 Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026